OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
With vaccine development prioritized during the COVID-19 pandemic, innovations have to accelerated development processes.
The inhaled route of administration for biologics is experiencing renewed interest.
June 11, 2021
Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.
June 08, 2021
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
FDA has granted fast track designation to a GLP-1/glucagon dual agonist in development by Boehringer Ingelheim and Zealand Pharma for the treatment of NASH.
FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.
June 04, 2021
Well-defined studies are crucial to effective process development.
June 03, 2021
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.
June 02, 2021
GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.
Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
Controlling certain atmospheric conditions in a closed NGI processing chamber can reduce bioburden without disinfectants.